← AlphaSignal

VRTX

★★☆☆☆ Passopenrouter

Vertex Pharmaceuticals Incorporated

Healthcare

Session move

$528.19

+$12.64+2.45%

Vol 1.10× avg

64/100 quant · tgt $563.12

RS60 +18.2% vs SPY · ADV$ 671.8M

pushed 2026-08-19T10:27 · Pre-market · Pushed snapshot

Since last scan

2026-08-18 → 2026-08-19

Score+2.2Price+$12.64 · +2.45%Disclosure+8.0

Context only — not a buy/sell signal. Built from scan history and cached news/filings.

Snapshot quote

session 2026-08-18 · scan 2026-08-19 · pushed 2026-08-19T10:27 · Pre-market

Show quote fundamentals
Last (scan/close)
$528.19
Previous close
$515.55
Pushed last
$528.19 · Pre-market
Session open
$520.00
Last session range
$517.34 – $533.78
52-week range
$374.17 – $546.17
Session volume
1,496,849
Avg volume (20d)
1,358,067
Market cap
$133.79B
PE (TTM)
30.03
Forward PE
24.21
Dividend yield
0.00%
1y target est.
$563.12
Next earnings
2026-11-02

Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. Pre/after-hours quotes are thinner and may differ from the regular session.

If you put $1,000 in

1y ago

$1,352

+35%

5y ago

$2,697

+170%

Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.

Market briefing

Curated digest — not a trade signal. Headlines and links as provided by the producer.

No recent headlines for this ticker.

Reddit mentions

Public Reddit titles via the official API — unofficial, delayed, not a trade signal. Not affiliated with Reddit. Opens Reddit.

No recent Reddit titles matched this ticker.

Price Chart

Daily prices from cache

Loading price history…

AI Analysis

  • Bull Thesis — Vertex Pharmaceuticals is well-positioned for growth with a solid revenue increase of 12.5% YoY and a strong FCF margin of 20.9%, driven by its innovative therapies in cystic fibrosis and expanding pipeline.
  • Risks — Potential risks include high valuation metrics with a trailing P/E of 30.03 and increasing debt-to-equity ratio at 9.77, which may impact financial flexibility.
  • Target Upside — With a target mean price of $563.12, Vertex Pharmaceuticals offers an upside potential of approximately 6.6% from its current price of $528.19.

Score History

2026-08-0163.9 pts · 2026-08-19

10 days of scans. Daily batch adds the next weekday automatically while the API is running.

  • DatePriceChgScoreRating
  • 2026-08-19$528.19+12.6463.9Pass
  • 2026-08-18$515.55+9.8061.8Pass
  • 2026-08-17$505.75-10.6963.0Pass
  • 2026-08-14$516.44-0.1562.5Pass
  • 2026-08-13$516.59-13.0662.5Pass
  • 2026-08-12$529.65+5.7455.9Pass
  • 2026-08-11$523.91+39.8864.8Pass
  • 2026-08-07$484.03+13.3159.4Pass
  • 2026-08-03$470.72-6.3877.3Watch
  • 2026-08-01$477.10—72.6Watch

Quant Breakdown

Revenue Growth
5.0
EPS Growth
3.2
ROE
11.3
PER Relative
3.1
Debt / Equity
8.0
FCF Margin
8.0
Analyst Upside
2.2
Insider / Sector
5.0
Momentum 3M
12.0
Earn. Surprise
6.1

Short volume (FINRA)

Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.

Elevated vs 20das of 2026-08-18 · finra_cnms
Short / total
71.2%
vs 20d (z)
2.39
Short vol
355,231
Status
ok

Squeeze pressure score

full

51/100

Short leg
56
Call leg
57
Activity
3.5
Call vol share
55.4%
PCR (vol)
0.81
Call OI share
—
ATM IV
0.8%

FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.

Disclosure score

Rule-based News / Insider / Earnings legs from cached SEC filings — context only, not beat/miss or a buy signal.

No recent SEC filings or earnings calendar inputs in the score window yet.

Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.

Earnings surprise (quant context)

From Yahoo/public fundamentals cached on the last quant scan — not part of the disclosure event score, and not a buy signal. Figure can lag the latest print.

Last reported surprise +0.1%

Filings & events

Recent SEC disclosures and earnings dates — context only, not a trade signal.

as of 2026-08-04·sec_edgar·CIK 0000875320
Next earnings
2026-11-02yahoo_calendar
Last earnings
—

SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.